Immatics Announces Full Year 2022 Financial Results and Corporate Update
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target…
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target…
ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201…
Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash h…